| Course | NUR 635 Advanced Pharmacology |
|---|---|
| Topic | Topic 6 |
| Paper type | Risk-benefit analysis |
| Length | About 960 words, 4 pages |
| Format | APA 7 student paper |
| School | Grand Canyon University (GCU) |
| Program | MSN |
| Updated | October 2026 |
Free sample paper for NUR 635 Topic 6
Twelve Years of Clonazepam and One Broken Wrist: A Risk-Benefit Analysis of Continuing Versus Tapering in a 66-Year-Old Woman With Panic Disorder in Remission
[Author Name]
College of Nursing and Health Care Professions, Grand Canyon University
NUR-635: Advanced Pharmacology
Topic 6 Assignment
[Instructor Name]
February 18, 2030
The organization, setting and figures below are a composite written as a model document. No real employer, client, colleague or patient is described.
Twelve Years of Clonazepam and One Broken Wrist: A Risk-Benefit Analysis of Continuing Versus Tapering in a 66-Year-Old Woman With Panic Disorder in Remission
The Patient, the Problem and What Has Been Tried
Ms. R., a composite 66-year-old retired librarian, has taken clonazepam 1 mg twice daily for 12 years for panic disorder. She has had no panic attacks for about eight years. Five weeks ago she fell on an icy step and fractured her left wrist; she took hydrocodone-acetaminophen for 10 days afterward. Most evenings she has a glass or two of wine and uses continuous positive airway pressure for obstructive sleep apnea. She has noticed that she searches for words more than she used to. Sertraline was tried 11 years ago and stopped after two weeks because of nausea; she has never had cognitive behavioral therapy. The question is whether to continue clonazepam or taper it.
The Expected Benefit, as She Would Notice It
Continuing clonazepam offers one benefit she would notice: the confidence that panic attacks will not return. How much of that protection the drug still provides after 12 years is uncertain; no trial quantifies it, and some of her remission may reflect the natural course of the disorder rather than continued drug effect. Tapering offers different benefits: a lower risk of falls and fractures, possibly clearer thinking, and removal of a dangerous interaction with alcohol and any future opioid. The chance that a taper succeeds can be quantified. In a meta-analysis of randomized trials in older people, supervised withdrawal combined with psychotherapy gave about five times the odds of being free of benzodiazepines afterward compared with usual care or comparison interventions (Gould et al., 2014).
The Risks, Separated by Frequency and Severity
The risks of each course differ in how often they occur and how much harm they cause, and they need different conversations.
Table 1
Risks of Continuing and of Tapering Clonazepam
| Course | Risk | Frequency | Severity |
|---|---|---|---|
| Continue | Falls and hip fracture; pooled relative risk of hip fracture 1.52 with benzodiazepines | Common in her age group | Serious |
| Continue | Slowed thinking and memory complaints | Common | Moderate |
| Continue | Breathing suppression with alcohol, opioids or untreated sleep apnea | Rare | Potentially fatal |
| Taper | Withdrawal symptoms: insomnia, anxiety, irritability | Common | Usually moderate and temporary |
| Taper | Return of panic attacks | Possible | Moderate, treatable |
| Taper | Withdrawal seizures | Rare with slow tapering | Serious |
Note. Hip fracture figure from Donnelly et al. (2017). Other frequencies are qualitative.
Weighing Them for This Patient
For a 66-year-old who has just fractured a wrist in a fall, who drinks most evenings and who has sleep apnea, the risks of continuing are not abstract, and they outweigh the uncertain benefit of a drug protecting against attacks she has not had in eight years. Benzodiazepine use was associated with a 52 percent higher risk of hip fracture in a meta-analysis of observational studies (Donnelly et al., 2017), and her recent fall shows that her risk is not theoretical. Current guidance for older adults advises avoiding benzodiazepines because of their effects on cognition, falls, fractures and driving (American Geriatrics Society Beers Criteria Update Expert Panel, 2023). Her nightly alcohol and her sleep apnea add to the danger of breathing suppression, and a future injury could easily bring another opioid prescription.
The risks of tapering are real but mostly manageable. Withdrawal symptoms and a return of anxiety can be reduced by a slow taper and treated with psychotherapy; seizures are rare when the dose is reduced gradually. The one argument for continuing, her fear that panic will return, is best met with a treatment that works on panic directly. Two middle courses were considered and set aside. Reducing to a lower maintenance dose and staying there would lower but not remove the fall risk, and it leaves the harder part of the taper for a later, older version of her. Switching to another benzodiazepine offers no advantage, since clonazepam's long half-life already makes it one of the easier agents to taper.
Monitoring That Makes the Accepted Risk Manageable
At each taper step, she will rate panic symptoms on the Panic Disorder Severity Scale, keep a diary of attacks and sleep, and report withdrawal symptoms. A rise of 5 or more points on the scale or attacks more than once a week will pause the taper at the current dose for four weeks rather than reverse it. Alcohol use will be reviewed at each visit with the aim of stopping alcohol during the taper. A fall, new confusion or daytime drowsiness will prompt an unscheduled visit. Her pharmacy will dispense no more than a month at a time, with a note that no opioid should be added without contacting the prescriber.
The Conversation, the Decision and the Stopping Plan
Ms. R. was told plainly that clonazepam has probably contributed to her fall, that continuing it carries a continuing risk of another fracture and that stopping it suddenly would be dangerous. She was told that the taper would be slow, that she could pause it if anxiety increased and that cognitive behavioral therapy for panic would begin before the first dose reduction. She said her greatest fear was losing control in public again. She preferred to wait until her cast is removed in three weeks and asked whether she could go more slowly than proposed. That was agreed.
The stopping plan, fixed today: total daily dose 2 mg; reduce by 0.25 mg every two weeks down to 1 mg a day; then reduce by 0.125 mg every two to four weeks to zero, using the 0.125 mg orally disintegrating tablet. The taper will take about five to six months. Weekly cognitive behavioral therapy for 12 sessions begins two weeks before the first reduction. She declined an antidepressant for now because of her previous nausea; if panic attacks return during the taper, escitalopram at a low starting dose will be offered again. The next review is in four weeks.
References
American Geriatrics Society Beers Criteria Update Expert Panel. (2023). American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society, 71(7), 2052-2081. https://doi.org/10.1111/jgs.18372
Donnelly, K., Bracchi, R., Hewitt, J., Routledge, P. A., & Carter, B. (2017). Benzodiazepines, Z-drugs and the risk of hip fracture: A systematic review and meta-analysis. PLOS ONE, 12(4), Article e0174730. https://doi.org/10.1371/journal.pone.0174730
Gould, R. L., Coulson, M. C., Patel, N., Highton-Williamson, E., & Howard, R. J. (2014). Interventions for reducing benzodiazepine use in older people: Meta-analysis of randomised controlled trials. British Journal of Psychiatry, 204(2), 98-107. https://doi.org/10.1192/bjp.bp.113.126003
What the NUR 635 Topic 6 instructions ask for
Topic 6 in NUR-635 asks students to analyze the risks and benefits of a prescribing decision for one patient. Strong papers state the problem and what has been tried, describe the expected benefit in terms the patient would notice and say how certain it is. Students should separate risks by how often they occur and how much harm they cause, weigh them against this patient's circumstances, such as a recent fall, alcohol use or sleep apnea, and describe monitoring that makes any accepted risk manageable. The paper should record the conversation with the patient, the decision reached and the plan for stopping, including the steps and what would pause them. Where a trial reports a number needed to treat or harm, that figure belongs in the analysis.
How the NUR-635 Topic 6 example is put together
The finished example quantifies both sides as far as the evidence allows. The expected benefit is stated in terms of what this patient would notice, and where a number exists for how many patients benefit, it appears. The risk is documented rather than listed, with the frequency given and the serious risks separated from the common ones, since a frequent nuisance and a rare catastrophe require different conversations. Monitoring appears as the mechanism that makes an accepted risk tolerable. The example handles the agents in this group carefully, addressing dependence, withdrawal and the practical difficulty of stopping where relevant, and it states what the patient was told and what they decided.
Reading the NUR 635 Topic 6 rubric
Faculty reward risks weighed against one patient's circumstances. An Excellent analysis states the expected benefit of clonazepam as confidence that panic will not return and admits the uncertainty after 12 years. Credit goes to separating risks by frequency and severity, using the Beers Criteria and Donnelly and colleagues. The rubric values weighing a recent wrist fracture, evening drinking and sleep apnea. Strong papers monitor each taper step with the Panic Disorder Severity Scale, with Gould and colleagues. Top marks go to a recorded conversation and a stopping plan.
NUR 635 Topic 6 help before you submit
Side effect lists offered where a weighing was required are the standard shortfall, since listing risks is not the same as balancing them against anything. A second weakness is benefit left unquantified, which makes the comparison impossible: a risk of any size outweighs a benefit nobody described. Papers lose marks for recommending caution as a conclusion, which decides nothing and leaves the clinical question open. Failing to plan discontinuation for an agent that is difficult to stop is a serious omission in this group specifically. Omitting the patient's own view treats a preference sensitive decision as though it were purely technical, which several rubrics penalize directly. Risks cited without a source read as recollection, which is not adequate at this level.
Get an NUR-635 Topic 6 example written to your instructions
Send the NUR-635 Topic 6 instructions and the rubric posted in your classroom, with the patient and agent your section assigned. We write a custom example to those criteria, with the benefit quantified, risks separated by frequency and severity, the balance struck for this patient and a stopping plan written in, in 24 to 48 hours. The first is free.
More NUR 635 papers and MSN samples
- NUR 635 Topic 1: Pharmacokinetics Application
- NUR 635 Topic 2: Antimicrobial Selection Rationale
- NUR 635 Topic 3: Cardiovascular Prescribing Analysis
- NUR 635 Topic 4: Respiratory Therapy Plan
- NUR 635 Topic 5: Apixaban Drug Selection Paper
- NUR 635 Topic 7: Special Population Dosing
- NUR 635 Topic 8: Comprehensive Prescribing Case
- NUR 641EA Topic 6: Misconception Diagnostic Item Set
- NUR 634 Topic 6: Musculoskeletal and Neurologic Exam
- NUR 643EA Topic 6: Reflex Exam Across Three Ages
- NUR 631 Topic 6: Acid-base Interpretation
NUR 635 Topic 6 questions, answered
How do I quantify a benefit?
Use whatever the evidence provides and say what it means for one person. Where a trial reports how many patients need treatment for one to benefit, that number belongs in the paper. Where the evidence gives only a symptom improvement, describe what the patient would actually notice and over what timeframe. An unquantified benefit cannot be weighed against a quantified risk, and the comparison collapses.
Should the patient's preference appear in the analysis?
Yes, and its absence is marked. These decisions are preference sensitive: a patient willing to accept sedation for pain relief and one who is not should receive different prescriptions from the same evidence. Recording what they were told, in what terms, and what they chose demonstrates the shared decision the rubric is usually assessing alongside the pharmacology.
Why plan discontinuation before starting?
Because several agents in this group are considerably harder to stop than to start, and a plan made at the beginning is easier than one improvised after months of use. State the intended duration, the review point, and the taper if one is needed. Prescriptions begun without an endpoint tend to continue indefinitely, which is how a short course becomes a long term medication nobody decided on.
Where can I find a free NUR 635 Topic 6 sample paper?
The analysis for NUR 635 Topic 6 covers the patient and problem, the expected benefit, risks separated by frequency and severity, weighing them for this patient, monitoring and the conversation, decision and stopping plan. Forward the NUR 635 Topic 6 prompt you received for a free paper.
Is tapering clonazepam always the right answer in NUR 635 Topic 6?
No. The paper reaches a taper for this patient because of the fall, alcohol and sleep apnea, and says that a different patient could reasonably continue.